Sino Biopharm Completes F-Star Acquisition After US CFIUS Review

 
• By Dexter Jie Yan

Sino Biopharm's $161m all-cash acquisition of F-star has finally closed amid heightening US-China tensions and following completion the Chinese firm, through its UK subsidiary invoX, plans to expand its operations and presence at F-star’s UK headquarters.

China go shopping
Chinese biopharma companies are on the lookout for opportunities to acquire foreign assets. • Source: Shutterstock

More from China

More from Focus On Asia